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Needless to say of course, that accumulation of collected
Fabry Registry data will contribute to evidence-based
care.
Regarding the comment on Fabry disease in women,
I agree that with time there is an increasing recognition
of clinical manifestations of the disease in female het-
erozygotes, and as I mentioned in the Forum discussion,
genetic and nongenetic factors can influence the sever-
ity and progression of the outcome. Although no females
have been included in the two large clinical trials (as ref-
erenced in the Forum and also cited by Dr. Kleinert et al),
it is also suggested that carriers with substantial disease
manifestations should be treated with ERT [2].
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The search for maturity. . .
To the Editor: Recently, my American colleagues pub-
lished results in the treatment of nonmaturing fistulas.
Their views differ from mine, and they referred to my
publications in a derogatory fashion [1]. I wrote that a
stenosis is diagnosed in all cases of delayed maturation
[2]. In 1997, Beathard diagnosed stenosis in 33% of cases
[3], and this rate has now skyrocketed to 78%. There is
no doubt that he will reach my rate of 100% in a future
article. He would first have to perform angiograms by ar-
terial puncture at the elbow to diagnose stenoses located
in proximal arteries.
I wrote that there is no opacification of collaterals with-
out stenosis of the main outflow vein. Figure 2 of Beat-
hard’s article is very informative because it shows an an-
giogram before occlusion of a tributary, but the authors
overlook the stenosis of the main vein, which explains
why this collateral was opacified (Fig. 1) [1].
Figure 1B [1] of the article shows that dilation of the
vein caused stenosis in the artery, which the authors over-
looked, and I am skeptical about the ability of this fis-
tula to deliver sufficient flow. This case should have been
treated by surgical creation of a new anastomosis, which
leads to higher patency rates [4].
Finally, the authors report amazingly high patency rates
and compare them to mine in a derogatory manner. I
treated truly immature fistulas with a mean age of 2.5
months compared with 4.5 in their article, and I salvaged
thrombosed fistulas, whereas they did not.
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Differential diagnosis between
X-linked Alport syndrome and
thin basement membrane
nephropathy
To the Editor: We read with interest the edito-
rial by Gregory [1] to the article “COL4A3 mutations
and their clinical consequences in thin basement mem-
brane nephropathy (TBMN).” Correctly, the necessity is
stressed to clearly distinguish thin basement membrane
nephropathy (TBMN) from Alport syndrome (AS), es-
pecially when the family history of renal failure and deaf-
ness is lacking. We believe that some complementary in-
formation should be given.
When renal biopsy is not typical [only thin glomerular
basement membrane (GBM)], the immunohistochem-
istry evaluation for a(IV) chains in the GBM can eas-
ily distinguish TBMN from Alport syndrome because in
the latter a3/a4/a5 chains are abnormally distributed or
even absent [2, 3]. In addition, the use of skin biopsy has
been demonstrated to be a very useful tool for diagnosing
X-linked AS. The reliability of skin immunohistochem-
istry for diagnosis of X-linked AS has been estimated in
about 80% in affected males and is a smaller percentage
in female carriers [4].
Very recently, the use of confocal laser microscopy in
the examination of the epidermal basement membrane
(EBM) had been proven to be able to detect a5(IV)
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chain altered distribution in a much higher proportion
of patients with X-linked AS [5].
It is our experience that skin biopsy, examined with
conventional, and if needed, with confocal microscopy,
is able to virtually detect (almost) all cases of X-linked
AS [5], thus allowing to avoid or to postpone more in-
vasive and/or expensive diagnostic procedure like renal
biopsy and genetic investigations, which, in addition, are
not diagnostic in all cases.
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Reply from the Author
I thank Professors Kashtan and Rizzoni and Dr. Mas-
sella for their comments. They rightly point out the value
of immunostaining of renal biopsies for the diagnosis of
X-linked and autosomal Alport syndrome and the utility
of skin immunofluorescence in diagnosis of many cases
of X-linked Alport syndrome. The use of confocal laser
scanning microscopy (CLSM) [1–3] is an elegant tech-
nique to improve the spatial resolution of a5(IV) chain
distribution in basement membranes.
Ueda et al [3], also using CLSM, have reported that
compared with a2(IV), a5(IV) expression in GBM is re-
duced in patients with TBMD. The reduction in a5(IV)
but not a3(IV) and a4(IV) is difficult to reconcile with
the genetic evidence implicating mutations of COL4A3
and COL4A4 in TBMD.
Confirmation and clarification of the results of CLSM
of EBM and GBM is eagerly awaited. Until sequenc-
ing of the relevant collagen genes or other comprehen-
sive genetic testing is routinely and readily available, im-
munofluorescence of skin biopsies is a minimally invasive
means for diagnosis of many cases of X-linked Alport syn-
drome. If quantitative comparisons of the different a(IV)
chains in GBM permit a positive diagnosis of TBMD, this
will further strengthen our diagnostic hand.
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Diagnosis of Alport syndrome
To the Editor: Professor Gregory’s recent editorial [1]
addresses the difficulties that may arise in attempts to
distinguish Alport syndrome and thin basement mem-
brane nephropathy, particularly in children. Positive di-
agnosis of the X-linked and autosomal-recessive forms of
Alport syndrome may be made by immunostaining of re-
nal biopsy specimens for alpha chains of type IV collagen
[2, 3]. X-linked Alport syndrome can also be diagnosed by
immunostaining of skin biopsy specimens for the alpha5
chain of type IV collagen [4].
There are patients who exhibit expression of type
IV collagen chains that is indistinguishable from con-
trol, despite the presence of pathogenic mutations in the
COL4A3, COL4A4, or COL4A5 gene [3, 4]. In these
cases, estimation of prognosis and genetic counseling
would be greatly aided by the availability of molecular ge-
netic diagnostic services. More than 80% of mutations in
the COL4A5 gene can be identified by direct nucleotide
sequencing [5].
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